mucos
immun
system
must
maintain
composur
presenc
onslaught
antigen
potenti
pathogen
materi
expos
outsid
world
case
singl
epitheli
cell
barrier
protect
mucos
surfac
develop
sophist
system
immun
exclus
ignor
toler
best
character
describ
gastrointestin
tract
understand
immun
respiratori
tract
lag
behind
gut
although
numer
key
compon
emerg
sequenc
event
initi
inhal
immun
patholog
lower
respiratori
tract
still
unclear
despit
best
effort
maintain
immun
homeostasi
respiratori
inflammatori
diseas
common
significantli
life
threaten
review
highlight
mechan
maintain
lung
immun
homeostasi
current
therapeut
effort
contain
infectioninduc
exagger
acut
inflamm
occur
respiratori
tract
includ
nasopharyng
caviti
trachea
larynx
bronchi
bronchiol
final
alveoli
organ
lymphoid
tissu
embed
importantli
stage
respiratori
tree
similarli
drain
lymph
node
associ
site
cellular
composit
requir
activ
expans
dynam
respiratori
tract
associ
lymph
node
virtual
similar
lymph
node
therefor
discuss
detail
focu
regul
deregul
immun
cell
embed
respiratori
tract
consid
total
surfac
area
respiratori
tract
constitut
embed
organ
lymphoid
tissu
actual
quit
rare
figur
organ
structur
lymphoid
tissu
exist
nasal
caviti
rodent
nasal
associ
lymphoid
tissu
nalt
pair
lymphoid
structur
entranc
pharyng
duct
ident
structur
man
remain
elus
review
see
refer
bienenstock
organ
lymphoid
follicl
observ
postmortem
specimen
extract
children
contain
occasion
germin
center
associ
lymphocyt
overli
nasal
epithelium
presenc
high
endotheli
venul
howev
adult
lymphoid
tissu
dissemin
across
whole
nasal
analog
less
wellorgan
diffus
lymphoid
tissu
term
dnalt
line
nasal
passag
man
diffus
nalt
develop
birth
like
respons
antigen
b
tcell
respons
parallel
occur
lymph
node
waldey
ring
compris
nasopharyng
upper
midlin
nasopharynx
adenoid
pair
tubal
around
open
auditori
tube
pair
palatin
either
side
oropharynx
lingual
mucosa
posterior
third
tongu
tonsil
thought
analog
structur
nalt
locat
outsid
respiratori
tract
probabl
also
contribut
gastrointestin
immun
experi
mice
show
unlik
peripher
lymphoid
organ
nalt
develop
independ
howev
structur
function
perturb
mice
possibl
due
impair
express
chemokin
crucial
recruit
placement
lymphocyt
dendrit
cell
dc
organ
lymphoid
structur
describ
date
locat
within
respiratori
tract
bronchusassoci
lymphoid
tissu
balt
review
bienenstock
whether
routin
contribut
primari
immun
respons
mainten
bcell
memori
respiratori
tract
howev
recent
studi
mice
lack
peripher
lymphoid
organ
suggest
balt
initi
antiinfluenza
immun
provid
suffici
cell
mediat
protect
second
humor
immun
respons
elicit
balt
primarili
mediat
immunoglobulin
iga
igg
produc
local
baltderiv
b
cell
traffic
distant
mucos
similarli
locat
tcell
respons
note
basi
find
balt
thought
function
analog
mucos
lymphoid
aggreg
intestin
present
children
adolesc
age
balt
rare
lung
healthi
although
origin
describ
bifurc
bronchi
immedi
beneath
absenc
antigen
balt
may
control
limit
regulatori
inflamm
lung
associ
balt
neogenesi
describ
varieti
pulmonari
moyronquiroz
et
refer
therein
inflammatori
condit
homeostat
chemokin
includ
mice
requir
develop
induc
balt
ibalt
extent
ibalt
appear
depend
level
inflamm
local
microenviron
suggest
develop
requir
mice
lack
oxidoreductas
protect
oxid
stress
display
heighten
cellular
inflammatori
cytokin
ibalt
whether
remain
associ
larger
airway
persist
long
resolut
inflamm
still
uncertain
intriguingli
mice
lack
peripher
lymph
node
spleen
retain
ibalt
clear
influenza
infect
albeit
slower
surviv
higher
dose
viru
immunecompet
mice
lymphotoxinknockout
mice
show
slower
gener
influenzaspecif
cell
eventu
reach
wildtyp
level
similar
antibodi
isotyp
switch
igg
tcell
cytokin
product
effector
function
indic
immun
respons
gener
ibalt
although
slower
protect
potenti
less
may
repres
qualit
differ
local
peripher
deriv
immun
cell
simpli
reflect
reduc
magnitud
immun
ibalt
induc
immun
compart
regardless
case
lung
immun
secondari
lymphoid
tissu
essenti
mainten
immunolog
memori
sinc
pulmonari
infect
influenza
viru
handl
equal
effici
date
studi
shown
organ
embed
lymphoid
tissu
ibalt
nalt
contribut
directli
inflammatori
patholog
lung
may
initi
product
immun
b
cell
track
less
organ
lung
immun
neogenesi
ibalt
continu
presenc
nalt
per
se
associ
patholog
instead
patholog
lung
inflamm
attribut
compart
lack
organ
lymphoid
structur
airway
lung
parenchyma
could
also
said
inflamm
gut
peyer
patch
mesenter
lymph
node
may
directli
associ
patholog
wherea
lamina
propria
lamina
propria
lung
parenchyma
common
loos
scatter
nonorgan
immun
cell
vast
surfac
area
potenti
nonprofession
antigenpres
cell
apc
epithelium
epithelium
express
constitut
mhc
class
inflam
mhc
class
ii
therefor
process
present
antigen
activ
cell
turn
believ
nonprofession
lack
immunecel
organ
lead
immun
dysregul
inflamm
mediastin
lymph
node
ibalt
expand
organ
precis
compartment
manner
although
low
frequenc
antigenspecif
cell
observ
ratio
immunecel
subset
significantli
chang
contract
lungassoci
lymph
node
also
well
control
cell
proport
retain
lung
compart
devoid
organ
lymphoid
tissu
howev
immun
cell
recruit
drove
chemotact
infect
epithelium
andor
tissu
resid
alveolar
macrophag
lung
parenchyma
airway
form
structur
analog
ibalt
lymph
node
patholog
damag
occur
tolllik
receptor
ligand
domin
inflammatori
cytokin
produc
infiltr
abund
unlik
lungassoci
lymph
node
airway
lung
parenchyma
therefor
experi
dramat
shift
cellular
composit
illustr
graphic
figur
approxim
cellular
composit
nalt
airway
lung
shown
homeostasi
peak
respiratori
infect
three
differ
pathogen
influenza
viru
bacterium
streptococcu
pneumonia
fungu
cryptococcu
neoforman
obvious
stage
infect
slightli
differ
cell
domin
peak
inflamm
present
clariti
exampl
natur
killer
cell
domin
airway
day
viral
peak
activ
influenzainfect
airway
lung
domin
wherea
pneumonia
infect
macrophag
neutrophil
cell
neoforman
mice
induc
eosinophildomin
respons
lung
infiltr
air
space
lung
pathogen
dramat
differ
site
homeostasi
contain
lymphoid
cell
promin
macrophag
note
nalt
despit
infect
three
pathogen
substanti
alter
proport
immunecel
subset
present
also
true
rel
noninfect
lung
drain
lymph
node
lack
control
excess
respons
observ
minor
occur
life
threaten
us
respiratori
pathogen
clear
noninflammatori
mean
includ
iga
fix
complement
well
dimer
form
agglutin
physic
exclud
antigen
process
known
immun
therefor
goe
wrong
minor
address
question
need
understand
immun
homeostasi
maintain
health
nonorgan
lung
compart
review
pathway
contribut
immun
patholog
epitheli
cell
contribut
multitud
strategi
maintain
lung
immun
homeostasi
review
see
refer
addit
barrier
function
secret
varieti
antimicrobi
substanc
surfact
protein
c
mucin
antimicrobi
peptid
affect
airway
smoothmuscl
dc
memori
tcell
activ
via
nitric
oxid
product
assist
cell
recruit
via
product
cytokin
chemokin
prolong
cell
surviv
secret
stimul
factor
colonystimul
raz
highlight
interest
pathway
critic
maintain
alveolar
macrophag
homeostasi
involv
integrin
local
cell
next
epitheli
express
transform
growth
may
explain
cell
refractori
migrat
drain
lymph
inflamm
proceed
inhibitori
pathway
must
overcom
mediat
tolllik
receptorinduc
conform
chang
macrophag
disrupt
signal
reduc
integrin
express
often
assum
innat
immun
inact
absenc
antigen
howev
work
raz
et
al
clearli
show
activ
suppress
requir
homeostasi
also
observ
mice
lack
compon
nadph
heighten
basal
level
airway
macrophag
activ
due
loss
feedback
inhibit
activ
suppress
mechan
therefor
set
threshold
ignor
succumb
continu
inflammatori
lung
diseas
may
therefor
dysregul
homeostat
pathway
threshold
antigen
must
exceed
induc
inflamm
set
low
case
suppress
alveolar
macrophag
homeostasi
overcom
cleavag
integrin
tether
respiratori
epithelium
homeostasi
restor
macrophagereleas
matrix
metalloproteinas
transform
latent
activ
may
therefor
possibl
har
pathway
artifici
dampen
inflammatori
lung
diseas
caveat
pathogen
clearanc
may
affect
global
antiinflammatori
macrophag
particularli
airway
long
known
immunesuppress
phenotyp
renew
achiev
primarili
via
local
cell
prolifer
recruit
via
occur
although
cell
may
take
day
matur
classic
immunesuppress
addit
shield
immun
system
inhal
display
poor
phagocyt
tend
migrat
well
drain
lymph
node
macrophag
held
homeostasi
also
affect
cell
type
may
otherwis
proinflammatori
within
respiratori
tract
review
see
refer
dc
migrat
drain
lymph
node
enhanc
upon
macrophag
tcellmedi
inflammatori
diseas
ensu
antigen
would
otherwis
like
due
usual
direct
suppress
influenc
alveolar
macrophag
dc
myeloid
plasmacytoid
dc
pdc
present
within
lung
increas
recruit
rapidli
inflamm
attract
chemokin
cytokin
produc
epitheli
cell
alveolar
myeloid
dc
respons
similar
counterpart
found
elsewher
bodi
pdc
howev
also
appear
play
tolerogen
role
respiratori
tract
poor
apc
activ
enhanc
tcell
respons
possibl
cell
distant
promot
inhal
protect
develop
allerg
airway
diseas
review
de
heer
et
hammad
acut
respiratori
viral
infect
pdc
perform
dual
function
promot
viral
clearanc
secret
type
interferon
ifn
limit
inflamm
induct
review
grayson
role
limit
lung
inflamm
clearli
seen
respiratori
syncyti
viru
rsv
infect
mice
pdc
deplet
lead
increas
viral
replic
enhanc
immunopatholog
dc
encount
antigen
predominantli
lung
parenchyma
although
microbi
sampl
via
dendrit
project
epitheli
cell
airway
lumen
may
induc
activ
matur
migrat
arm
support
potent
tcell
quit
return
cell
homeostasi
unknown
may
involv
level
tolllik
receptor
signal
andor
influenc
surfac
express
inhibitori
receptor
airway
epitheli
cell
may
also
control
dc
activ
via
analog
alveolar
although
proven
whether
dc
actual
transmigr
airspac
still
assist
transit
across
endothelium
subsequ
migrat
recent
describ
dc
express
requisit
chemokin
receptor
draw
presenc
compart
proven
clearli
har
homeostat
pathway
describ
may
help
resolv
ongo
inflamm
howev
equal
like
immun
cell
type
pathway
brought
lung
inflammatori
cell
inflamm
also
provid
therapeut
opportun
would
possibl
cover
pathway
attempt
limit
lung
inflamm
therefor
restrict
analysi
acut
infecti
event
ie
asthma
target
therapeut
strategi
ie
global
antiinflammatori
corticosteroid
experi
genedelet
anim
immunemedi
patholog
manipul
stage
gener
clinic
perspect
howev
onset
identifi
symptom
would
benefici
reason
often
resolut
inflamm
target
includ
modul
cell
surviv
success
wave
recruit
ongo
innat
immun
still
unclear
whether
immun
excess
respiratori
tract
stem
overexuber
recruit
prolifer
within
airspac
andor
accumul
absenc
clearanc
innat
adapt
immun
cell
evid
suggest
airspac
may
support
effici
tcell
despit
memori
cell
acquir
bromodeoxyuridin
stain
rate
secondari
lymphoid
like
inflammatori
cytokin
chemokin
cascad
ensu
upon
prolong
immunecel
surviv
time
enhanc
recruit
either
directli
alter
vascular
epitheli
inflammatori
environ
also
associ
highest
express
late
costimulatori
molecul
cell
prevent
activationinduc
cell
death
reli
cognat
ligand
express
apc
signal
one
late
costimul
restrict
recent
activ
cell
wherea
ligand
express
number
cell
type
predominantli
stimul
promot
tcell
surviv
clonal
inhibit
regulatori
enhanc
immun
varieti
howev
acut
influenza
viru
infect
mice
transient
blockad
benefici
allevi
ill
patholog
influenza
without
compromis
pathogen
clearanc
immunolog
perman
absenc
multipl
late
costimul
howev
compromis
immunolog
manipul
one
late
costimulatori
pathway
therefor
leav
other
intact
seed
memori
tcell
suggest
full
compliment
late
costimul
may
actual
prolong
tcell
surviv
contribut
patholog
inflammatori
cytokin
abundantli
express
airway
infect
known
increas
due
lack
immun
organ
airway
late
costimulatori
molecul
ligand
may
downregul
late
avoid
bystand
tissu
damag
observ
inflam
endothelium
highlight
difficulti
separ
effect
immun
modul
cell
surviv
vs
cell
especi
ligat
endotheli
cell
induc
secret
like
restrict
lateeffector
cell
absenc
blockad
impair
tcell
respons
although
effect
associ
respiratori
patholog
yet
known
care
must
taken
howev
sinc
induc
costimul
result
benefici
outcom
block
lung
influenza
infect
ico
blockad
impair
respiratori
cell
extent
viru
escap
similar
treatment
influenzainfect
mice
fusion
protein
block
bind
molecul
mice
infect
c
macrophag
antimicrobi
strategi
impair
like
target
may
also
produc
untoward
side
effect
sinc
express
rest
memori
cell
crucial
format
tcell
perhap
defin
line
therapeut
potenti
place
late
costimul
absolut
depend
tcell
receptor
constitut
signal
express
appear
bystand
fashion
presenc
inflammatori
cytokin
like
effect
costimulatori
blockad
site
manipul
may
effect
shown
figur
addit
late
costimulatori
molecul
number
pathway
affect
longev
lung
inflamm
acut
infect
whether
apoptosi
benefici
harm
depend
specif
infect
domin
cell
type
mediat
gener
rule
apoptosi
favor
host
chronic
acut
intracellular
bacteri
viral
infect
process
clear
pathogen
detriment
extracellular
exampl
infect
rat
pneumocysti
alveolar
macrophag
apoptosi
delay
clearanc
organ
improv
administ
similarli
apoptosi
airway
epitheli
cell
via
fasfa
ligand
essenti
prevent
dissemin
pseudomona
howev
influenza
infect
may
advantag
reduc
cell
surviv
especi
case
tnf
produc
cell
tnf
receptorii
late
antigen
synerg
protect
cell
influenza
viru
infect
airway
wherea
engag
transmit
neg
signal
limit
immun
may
therefor
possibl
resolv
tcell
inflamm
bystand
tissu
damag
occur
block
enhanc
surfac
receptor
viral
load
reduc
would
use
howev
strategi
specif
target
defin
cell
popul
sinc
apoptosi
airway
epitheli
cell
leukocyt
may
link
patholog
observ
infect
highli
pathogen
avian
furthermor
apoptosi
lead
system
observ
influenza
infect
may
assist
viru
propag
surviv
respiratori
pathogen
cytomegaloviru
parainfluenza
viru
use
antiapoptot
strategi
prolong
surviv
cell
chlamydia
block
apoptosi
affect
releas
cytochrom
c
extracellular
pathogen
pseudomona
cepacia
pneumonia
caus
apoptosi
neutrophil
airway
epitheli
cell
tabl
respect
aid
surviv
modul
apoptosi
therefor
complic
may
benefit
host
one
infect
would
compromis
anoth
recruit
traffick
leukocyt
respons
inflamm
tightli
regul
process
tip
balanc
protect
infect
immun
mediat
damag
lung
brief
involv
slow
roll
concomit
activ
leukocyt
increas
integrin
express
avid
regul
roll
arrest
adhes
strengthen
well
spread
intravascular
crawl
culmin
paracellular
transcellular
sinc
excess
cell
recruit
featur
mani
acut
lung
infect
target
specif
molecul
involv
abovement
event
may
benefici
block
monoclon
antibodi
integrin
late
natalizumab
lymphocyt
functionassoci
efalizumab
current
use
treat
inflammatori
autoimmun
disord
crohn
diseas
also
immunosuppress
studi
context
acut
respiratori
potenti
benefit
block
chemokin
receptor
use
competit
blocker
antagonist
compound
well
describ
review
glass
et
charo
secret
chemokin
bind
glucosaminoglycan
endotheli
cell
form
chemoattract
gradient
direct
cell
inflammatori
classifi
constitut
homeostat
inflammatori
requir
proinflammatori
stimulu
tnf
microbi
product
chemokin
receptor
transmembran
gproteincoupl
molecul
trigger
signal
transduct
event
result
activ
firm
adhes
migrat
interact
chemokin
receptor
function
redund
mani
chemokin
bind
receptor
one
chemokin
bind
sever
receptor
difficult
design
reliabl
therapeut
disrupt
interact
one
particular
chemokin
therapeut
administr
antibodi
block
macrophag
inflammatori
influenza
infect
reduc
neutrophil
recruit
improv
lung
patholog
without
alter
viral
howev
strategi
requir
test
coinfect
model
sinc
neutrophil
critic
clearanc
respiratori
bacteria
commonli
caus
secondari
pneumonia
presenc
influenza
rant
anoth
potenti
target
produc
respiratori
epitheli
cell
varieti
viral
infect
rant
induc
cell
eosinophil
monocyt
recruit
rsv
infect
express
infect
epithelia
resid
macrophag
secret
airway
first
h
infect
product
taken
newli
recruit
cell
block
chemokin
competit
inhibitor
metrant
primari
rsv
infect
reduc
lung
immunopatholog
howev
heighten
cell
recruit
occur
homolog
rsv
rechalleng
suggest
manipul
first
infect
sever
compromis
immunolog
strategi
test
mous
model
pneumonia
viru
infect
highli
lethal
mous
pathogen
induc
diseas
close
resembl
sever
human
rsv
infect
man
abrog
coadministr
antivir
agent
rivabirin
contrast
inhibit
chemokin
virusinduc
lung
inflamm
infect
may
requir
administr
p
aeruginosa
lung
infect
caus
airway
neutrophil
infiltr
rapidli
apoptos
becom
toxic
administr
recombin
monocyt
chemoattract
recruit
activ
lung
macrophag
clear
apoptot
neutrophil
caus
ifninduc
protein
critic
clearanc
klebsiella
also
produc
lung
viral
infect
neutral
may
mani
chemokin
receptor
also
increas
respiratori
viral
infect
exampl
upregul
murin
gammaherp
viru
infect
absenc
delay
viral
antagon
reduc
mortal
pneumoviru
infect
absenc
also
prevent
rsvinduc
exacerb
rel
littl
accomplish
area
especi
therapeut
howev
due
pauciti
reagent
avail
chemokinereceptor
blockad
anoth
method
alter
lymphocyt
migrat
manipul
sphingosin
receptor
requir
egress
lymphocyt
thymu
peripher
lymph
node
impact
vascular
permeabl
novel
synthet
immunosuppress
drug
inhibit
lymphocyt
emigr
lymphoid
organ
bind
activ
sphingosin
sphingosin
known
play
role
endotoxininduc
lung
injuri
affect
endotheli
barrier
current
trial
varieti
inflammatori
disord
includ
yet
test
acut
lung
infect
one
way
temper
innat
immun
matur
lung
microenviron
instil
probiot
microb
would
compet
surviv
pathogen
microorgan
oral
administr
lactobacillu
casei
lung
pneumonia
infect
protect
result
rapid
clearanc
shorter
period
septicemia
decreas
pneumonia
load
lung
benefit
attribut
increas
neutrophil
myeloperoxidas
limit
lung
tissu
damag
like
mediat
migrat
matur
apc
gut
lung
better
equip
bacteri
prior
infect
lung
also
benefici
effect
subsequ
acut
respiratori
infect
modif
matur
prior
influenza
infect
exampl
reduc
subsequ
tolllik
receptor
respons
alveolar
macrophag
prolong
period
administr
microbi
product
cpg
dna
modifi
bacteri
labil
toxin
also
protect
array
subsequ
respiratori
chronic
acut
infect
distant
abil
pathogenderiv
protein
modifi
acut
respiratori
infect
howev
yet
test
therapeut
resveratrol
polyphenol
compound
found
red
wine
inhibit
nuclear
activ
decreas
mortal
proinflammatori
cytokin
tnf
serratia
marcescen
pneumonia
rat
though
strategi
increas
neutrophil
number
resolv
similarli
acid
polysaccharid
compound
cordycep
militari
insectborn
fungu
antivir
properti
murin
influenza
infect
intranas
administr
fungal
polysaccharid
decreas
mortal
influenza
viral
titer
increas
lung
proinflammatori
cytokin
vitro
influenza
infect
macrophag
cell
line
treat
resveratrol
display
enhanc
induc
nitric
oxid
synthas
nitric
oxid
suggest
compound
may
function
nonspecif
stimul
alveolar
macrophag
enhanc
innat
adapt
immun
reduc
microbi
load
also
observ
upon
therapeut
administr
retino
acid
mice
infect
mycobacterium
increas
number
macrophag
natur
killer
cell
increas
express
tnf
induc
nitric
oxid
synthas
may
also
benefit
acut
respiratori
bacteria
fungi
though
viral
infect
would
predict
detriment
acut
respiratori
infect
yet
examin
critic
pathway
clearanc
pathogen
infect
lung
epitheli
cell
via
reactiv
oxygen
nitrogen
speci
contribut
host
defenc
mediat
pro
antiinflammatori
effect
review
mani
therapeut
treatment
discuss
time
extent
modul
associ
free
radic
critic
clear
consensu
literatur
exampl
success
intervent
pathway
rat
p
aeruginosa
pneumonia
treatment
inhal
postinfect
improv
bacteri
clearanc
direct
bactericid
effect
increas
recruit
neutrophil
enhanc
endotheli
k
pneumonia
infect
rat
inhal
also
suppress
bacteri
replic
decreas
lung
intercellular
adhes
express
myeloperoxidas
activ
tnf
level
nuclear
activ
thu
mani
paracrin
effect
inflammatori
cell
also
promot
bacteri
viral
infect
impact
manipul
less
clear
inhibit
rsv
infect
reduc
pulmonari
inflamm
bystand
tissu
damag
viral
replic
similar
therapeut
strategi
employ
reduc
local
concentr
reactiv
oxygen
speci
reactiv
nitrogen
speci
produc
infect
lung
epithelium
macrophag
rsv
infect
mice
administr
antioxid
butyl
hydroxyanisol
decreas
ill
score
weight
loss
lung
neutrophil
recruit
multifactori
attenu
inflamm
observ
influenzainfect
mice
treat
freerad
scaveng
manganes
superoxid
dismutas
within
h
infect
enzym
potent
antiinflammatori
properti
result
less
lung
consolid
improv
arteri
oxygen
satur
presum
result
decreas
tissu
reduc
tissu
damag
also
occur
mice
lack
superoxid
dismutas
treat
therapeut
mangan
porphyrin
scaveng
reactiv
oxygen
therefor
inhibit
reactiv
oxygen
speciesreact
nitrogen
speci
benefici
acut
respiratori
viral
infect
like
detriment
concurr
respiratori
bacteria
modul
immunereceptor
signal
infanc
regard
acut
respiratori
infect
may
limit
toxicitysafeti
profil
avail
drug
b
formul
challeng
vivo
deliveri
c
lack
specif
due
share
receptor
associ
problemat
pharmacokinet
sustain
blockag
detriment
protect
infect
drug
may
deliv
local
prevent
system
effect
truli
therapeut
manipul
date
abrog
airway
fluid
clearanc
rsv
infect
caus
interact
uridin
triphosph
purinerg
receptor
postinfect
administr
activ
metabolit
leflunomid
leflunomid
restor
airway
fluid
clearanc
provid
symptomat
relief
reduc
lung
inflamm
hypoxemia
without
impair
viral
replic
although
signal
molecul
associ
pattern
recognit
cytokin
receptor
well
describ
littl
known
complex
innat
pathway
induc
whole
pathogen
especi
control
signal
pathway
lead
exuber
inflamm
major
interest
balanc
need
struck
maintain
host
defenc
infect
feasibl
approach
might
treat
patient
peak
inflamm
immun
mediat
excess
use
drug
short
halflif
promis
strategi
knowledg
drug
target
signal
compon
report
efficaci
human
lung
infect
although
comprehens
review
relev
inhibitor
inflammatori
signal
pathway
found
receptor
recogn
pathogen
tolllik
receptor
nodlik
receptor
also
tnf
often
involv
amplif
inflammatori
respons
potent
activ
induct
key
factor
trigger
inflamm
influenzainfect
mice
treat
cellperm
peptid
reduc
level
via
effect
ikappab
kinas
beta
reduc
pulmonari
rsvinduc
strategi
may
neg
affect
respiratori
bacteria
sinc
intratrach
adenoviru
deliveri
domin
inhibitor
impair
clearanc
respiratori
p
despit
reduc
inflamm
observ
purifi
bacteri
peroxisom
proliferatoractiv
nuclear
receptor
involv
stress
respons
lung
injuri
attenu
inflammatori
respons
inhibit
mani
steroid
target
peroxisom
proliferatoractiv
show
encourag
result
model
lung
seri
natur
synthet
ligand
receptor
develop
rsvspecif
respons
human
lung
epitheli
cell
line
reduc
mitogenactiv
protein
kinas
cjunntermin
kinas
pathway
may
also
provid
futur
suitabl
target
activ
pathway
often
associ
induct
tolllik
receptor
respons
exampl
thought
maintain
inflammatori
respons
stabil
cytokin
inhibit
mitogenactiv
protein
kinas
pathway
may
therefor
favor
termin
inflamm
inhibitor
reduc
epitheli
disrupt
caus
rsv
bordetella
inhibit
pathway
knowledg
although
test
test
lung
infect
model
anoth
approach
reduc
pathogeninduc
immunopatholog
acut
infect
target
signal
molecul
involv
cell
migrat
downstream
chemokin
receptor
phosphatidylinositol
activ
protein
kinas
c
rho
phosphatidylinositol
inhibitor
reduc
recruit
neutrophil
cell
although
treatment
effici
allevi
chronic
inflamm
valid
acut
microbi
infect
addit
use
phosphatidylinositol
inhibitor
may
interfer
develop
innat
respons
identif
new
cytokin
seri
paper
describ
manipul
model
acut
infect
follow
detail
due
space
constraint
discuss
limit
test
therapeut
acut
lung
infect
model
first
typei
ifn
play
import
role
limit
viral
replic
develop
strategi
avoid
rna
viru
lung
infect
produc
predominantli
alveolar
macrophag
lesser
extent
pdc
whose
deplet
impair
viral
dose
doublestrand
rna
induc
h
sar
coronavirua
infect
reduc
lung
viral
similarli
rsv
human
metapneumovirusinfect
balbc
mice
treat
intranas
recombin
reduc
lung
viral
titer
inflammatori
diseas
compar
untreat
prophylact
treatment
sar
coronavirusinfect
macaqu
pegyl
significantli
reduc
viral
load
pulmonari
damag
postexposur
treatment
effect
although
produc
intermedi
recombin
therefor
appear
benefici
reduc
viral
replic
associ
patholog
administ
earli
infect
influenc
concomit
bacteri
infect
requir
examin
earli
innat
cytokin
import
respiratori
viral
bacteri
infect
includ
tnf
blockad
promot
howev
complic
fact
respiratori
bacteria
tend
requir
clearanc
exampl
rhinoviru
induc
antagonist
airway
epitheli
cell
facilit
resolut
howev
enhanc
bacteri
outgrowth
lung
mice
pneumococc
pneumonia
without
benefit
reduc
host
therefor
pathway
predict
good
one
lung
infect
bad
anoth
blockad
anoth
exampl
neutral
benefit
sever
lung
viral
impair
clearanc
lung
histoplasma
legionella
infect
list
continu
neutral
tnf
benefit
immun
patholog
induc
influenza
rsv
respiratori
bacteria
especi
treatment
prolong
although
depend
precis
strategi
webster
cowork
report
recent
absenc
tnf
benefit
murin
influenza
howev
surviv
observ
experi
genedeplet
anim
use
may
harbor
development
abnorm
virus
induc
local
product
nont
cell
respiratori
tract
neutral
reduc
local
lung
cellular
system
humor
respons
influenza
viru
infect
may
also
delay
viral
also
requir
clearanc
would
appear
new
cytokin
block
may
also
present
oppos
effect
viral
bacteri
lung
infect
suitabl
reagent
yet
develop
neutral
vivo
blockad
alon
combin
requir
develop
significantli
reduc
mycoplasma
pneumoniaeinduc
subsequ
bacteri
clearanc
possibl
via
reduc
neutrophil
pneumonia
clearanc
also
depend
influenc
neutral
respiratori
viral
infect
unknown
administr
immun
suppress
cytokin
consid
infect
induc
lung
inflammatori
diseas
encount
similar
problem
neutral
increas
surviv
mice
infect
k
contrast
influenza
induc
indoleamin
product
may
limit
lung
inflamm
howev
treatment
indoleamin
inhibitor
would
reduc
induc
reduct
lung
pneumonia
intranas
treatment
rsvinfect
mice
reduc
lung
nuclear
dnabind
activ
chemokin
gene
express
airway
similarli
administr
plasmid
reduc
inflamm
viral
fungal
lung
pathogen
without
except
prevent
although
plethora
strategi
use
modul
lung
inflamm
acut
infect
test
therapeut
onset
clinic
symptom
even
less
test
model
common
coexist
lung
pathogen
hundr
immun
modul
therefor
benefici
influenza
infect
bacteria
sometim
accompani
would
immun
therapeut
work
best
combin
antibiot
equal
select
immun
modul
requir
precis
determin
exactli
patient
infect
absenc
knowledg
may
appli
benefici
strategi
one
suppos
infect
creat
altogeth
differ
type
problem
sever
gap
remain
knowledg
immun
homeostasi
maintain
respiratori
tract
inflammatori
pathway
overcom
precis
effectormemori
phenotyp
immun
cell
within
airway
lung
parenchyma
controversi
also
still
surround
potenti
acut
respiratori
infect
persist
sinc
detect
pathogen
genom
common
studi
abl
demonstr
classic
reactiv
long
primari
infect
persist
exist
depend
natur
persist
organ
immun
modul
may
caus
reactiv
develop
sensit
tool
pathogen
detect
elucid
specif
gene
express
pattern
patient
acut
mean
futur
use
target
immun
modul
imposs
long
abl
strike
balanc
immun
patholog
immun
defenc
author
declar
conflict
interest
